asset: drug-price-transparency-thresholds

asset_type: obligation-threshold

body: State-by-state comparison of the dollar thresholds and percentage-increase triggers that require pharmaceutical manufacturers to report drug pricing information to state regulatory agencies. As of 2026, approximately 23 US states have enacted drug price transparency laws, each with different WAC (wholesale acquisition cost) thresholds for new drugs, different percentage-increase triggers for existing drugs, different reporting timeframes, and different penalty structures. Each record is one state with its reporting thresholds. Answers 'at what price or price increase must I report in [state]', 'what is the penalty for not reporting in [state]', and 'which states require drug price transparency reporting'.

key_field: state

licence: unknown

title: State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

type: dataset


body:
**State:** Connecticut

**Price increase % trigger:** 16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment

**Statute:** HB 6669

> HB 6669 updates the WAC increases that must be reported from a 20% WAC increase during the immediately preceding calendar year to a 16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

state: Connecticut

title: Connecticut — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

type: obligation-threshold

unverified_fields: state


body:
**State:** Florida

**Price increase % trigger:** 15% or more during the previous 12-month period or 30% or more cumulative during the preceding calendar years

**Statute:** Fla. Stat. § 499.026

> Fla. Stat. § 499.026 (2025), which requires drug manufacturers to report any WAC increase of 15% or more during the previous 12-month period or any cumulative WAC increase of 30% or more during the preceding calendar years.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

state: Florida

title: Florida — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

unverified_fields: state, statute_citation


body:
**State:** Louisiana

**New drug WAC threshold:** $100

**Price increase % trigger:** 50% for a 30-day supply

**Reporting deadline:** notification via email

**Implementing agency:** commissioner of insurance

**Statute:** LA. Stat. Ann. § 22:1657.1

> <https://legis.la.gov/Legis/Law.aspx?d=1108782#:~:text=Louisiana%20Laws%20-%20Louisiana%20State%20Legislature&text=A.,a%20condition%20of%20maintaining%20licensure.#:~:text=Louisiana%20Laws%20-%20Louisiana%20State%20Legislature&text=A.,a%20condition%20of%20maintaining%20licensure.> LA. Stat. Ann. § 22:1657.1 requires drug manufacturers to notify the commissioner of insurance if one of their drugs with a WAC 1 of $100 or more has undergone a WAC increase of 50% or more for a 30-day supply.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

implementing_agency: commissioner of insurance

price_increase_pct_trigger: 50% for a 30-day supply

reporting_deadline: notification via email

state: Louisiana

title: Louisiana — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers


body:
**State:** Minnesota

**Generic/biosimilar trigger:** 50% over the previous 12 months

**Statute:** S.F. 2995

> Minnesota : <https://www.revisor.mn.gov/bills/text.php?version=latest&number=SF2995&session=ls93&session_year=&session_number=0> S.F. 2995 amends the state’s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including “biosimilars” along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

generic_biosimilar_trigger: 50% over the previous 12 months

state: Minnesota

title: Minnesota — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers


body:
**State:** New Jersey

**New drug WAC threshold:** $670 per WAC unit

**Price increase % trigger:** more than 10% during any 12-month period

**Generic/biosimilar trigger:** generic drug priced at $10 or more by more than 10% during any 12-month period

**Statute:** NJ S.B. 1615

> NJ S.B. 1615 requires manufactures to report certain data points (e.g., NDC, sales volume, manufacturer costs, reasons for WAC increase) if it is increasing the WAC of a brand-name drug by more than 10% or increasing the WAC of a generic drug priced at $10 or more by more than 10% during any 12-month period. Additionally, the state requires reporting if a new drug has a WAC of $670 per WAC unit or more or a biosimilar has a WAC that is not at least 15% less than the WAC of a referenced brand biologic.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

new_drug_wac_threshold: $670 per WAC unit

state: New Jersey

title: New Jersey — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers


body:
**State:** New Mexico

**New drug WAC threshold:** $400 for a 30-day supply

**Price increase % trigger:** 10% in the previous calendar year or 16% over the previous two calendar years

**Reporting deadline:** first reporting deadline June 1, 2025

**Generic/biosimilar trigger:** 30% or more over the previous calendar year

**Statute:** NM HB 33

> NM HB 33 requires drug manufacturers to report to the state data for any (1) drugs with a WAC of $400 or more for a 30-day supply, (2) course of treatment that is shorter than 30 days for a brand-name drug that has increased in WAC by 10% or more in the previous calendar year or by 16% or more over the course of the previous two calendar years, or (3) a generic drug or biosimilar that has increased in WAC by 30% or more over the previous calendar year.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

new_drug_wac_threshold: $400 for a 30-day supply

reporting_deadline: first reporting deadline June 1, 2025

state: New Mexico

statute_citation: NM HB 33

title: New Mexico — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers


body:
**State:** New York

**Price increase % trigger:** more than 16%, including the proposed increase and the cumulative increases that occurred within the prior 24 months

**Reporting deadline:** within 60 days of the planned effective date of an increase in price

**Statute:** NY A1707

> NY A1707 requires manufacturers to file a notice within 60 days of the planned effective date of an increase in price for prescription drugs with a WAC of more than $40 for a course of therapy if the increase in WAC is more than 16%, including the proposed increase and the cumulative increases that occurred within the prior 24 months.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

state: New York

title: New York — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers


body:
**State:** Oregon

**New drug WAC threshold:** $950 for a 30-day supply

**Price increase % trigger:** 10 percent or more

**Reporting deadline:** New drug reports due within 30 days of market entry; Annual increase reports due March 15; 60-day price increase notices due 60 days before increase

**Implementing agency:** Division of Financial Regulation

**Generic/biosimilar trigger:** 25 percent or more AND the increase is $300 or more

**Statute:** ORS 646A.680 through 646A.692

> New drug reports due within 30 days of market entry Annual increase reports due March 15 (extended to April 15, 2026 for this year) 60-day price increase notices due 60 days before increase

Source: <https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx>

implementing_agency: Division of Financial Regulation

new_drug_wac_threshold: $950 for a 30-day supply

price_increase_pct_trigger: 10 percent or more

state: Oregon

title: Oregon — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

unverified_fields: generic_biosimilar_trigger, implementing_agency, new_drug_wac_threshold, price_increase_pct_trigger, state, statute_citation


body:
**State:** Texas

**New drug WAC threshold:** $100 for a 30-day supply

**Price increase % trigger:** 15% or more in the previous year or 40% or more over the past three years

**Implementing agency:** Texas Health and Human Services Commission

**Maximum penalty:** $1,000 per day

**Generic/biosimilar trigger:** same as brand

**Statute:** Tex. Health & Safety Code § 441.0051-441.0054

> 15% or more in the previous year or 40% or more over the past three years. If any FDA-approved drugs are sold in Texas, the manufacturer must also submit a report with the current WAC information to the Texas Health and Human Services Commission. Penalties for noncompliance may be up to $1,000 per day from the date on which such reporting is required, after 45 days from the date the manufacturer receives notice.

Source: <https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws>

generic_biosimilar_trigger: same as brand

new_drug_wac_threshold: $100 for a 30-day supply

penalty_max: $1,000 per day

state: Texas

title: Texas — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers